BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37628903)

  • 1. Genomic Evolution and Transcriptional Changes in the Evolution of Prostate Cancer into Neuroendocrine and Ductal Carcinoma Types.
    Rao SR; Protheroe A; Cerundolo L; Maldonado-Perez D; Browning L; Lamb AD; Bryant RJ; Mills IG; Woodcock DJ; Hamdy FC; Tomlinson IPM; Verrill C
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrative Genomic Analysis of Coincident Cancer Foci Implicates CTNNB1 and PTEN Alterations in Ductal Prostate Cancer.
    Gillard M; Lack J; Pontier A; Gandla D; Hatcher D; Sowalsky AG; Rodriguez-Nieves J; Vander Griend D; Paner G; VanderWeele D
    Eur Urol Focus; 2019 May; 5(3):433-442. PubMed ID: 29229583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma.
    Tan HL; Sood A; Rahimi HA; Wang W; Gupta N; Hicks J; Mosier S; Gocke CD; Epstein JI; Netto GJ; Liu W; Isaacs WB; De Marzo AM; Lotan TL
    Clin Cancer Res; 2014 Feb; 20(4):890-903. PubMed ID: 24323898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
    Chedgy EC; Vandekerkhove G; Herberts C; Annala M; Donoghue AJ; Sigouros M; Ritch E; Struss W; Konomura S; Liew J; Parimi S; Vergidis J; Hurtado-Coll A; Sboner A; Fazli L; Beltran H; Chi KN; Wyatt AW
    J Pathol; 2018 Oct; 246(2):244-253. PubMed ID: 30015382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
    Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
    BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIN-like ductal carcinoma of the prostate has frequent activating RAS/RAF mutations.
    Kaur HB; Salles DC; Paulk A; Epstein JI; Eshleman JR; Lotan TL
    Histopathology; 2021 Jan; 78(2):327-333. PubMed ID: 32740981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
    Hansel DE; Nakayama M; Luo J; Abukhdeir AM; Park BH; Bieberich CJ; Hicks JL; Eisenberger M; Nelson WG; Mostwin JL; De Marzo AM
    Prostate; 2009 May; 69(6):603-9. PubMed ID: 19125417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple Origin and Tumor Heterogeneity of Prostatic Ductal Adenocarcinoma in the Han Chinese Population.
    Zhang W; Su F; Wang M; Hou H; Liu M; Liu D; Liu H
    Genet Test Mol Biomarkers; 2021 Nov; 25(11):727-732. PubMed ID: 34788144
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Lindh C; Samaratunga H; Delahunt B; Bergström R; Chellappa V; Yaxley J; Lindberg J; Egevad L
    Prostate; 2022 Apr; 82(5):576-583. PubMed ID: 35049068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists.
    Mohanty SK; Lobo A; Williamson SR; Shah RB; Trpkov K; Varma M; Sirohi D; Aron M; Kandukari SR; Balzer BL; Luthringer DL; Ro J; Osunkoya AO; Desai S; Menon S; Nigam LK; Sardana R; Roy P; Kaushal S; Midha D; Swain M; Ambekar A; Mitra S; Rao V; Soni S; Jain K; Diwaker P; Pattnaik N; Sharma S; Chakrabarti I; Sable M; Jain E; Jain D; Samra S; Vankalakunti M; Mohanty S; Parwani AV; Sancheti S; Kumari N; Jha S; Dixit M; Malik V; Arora S; Munjal G; Gopalan A; Magi-Galluzzi C; Dhillon J
    Int J Surg Pathol; 2023 Sep; 31(6):993-1005. PubMed ID: 35946087
    [No Abstract]   [Full Text] [Related]  

  • 13. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate.
    Sanati S; Watson MA; Salavaggione AL; Humphrey PA
    Mod Pathol; 2009 Oct; 22(10):1273-9. PubMed ID: 19633648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of neuroendocrine prostate cancer.
    Conteduca V; Oromendia C; Eng KW; Bareja R; Sigouros M; Molina A; Faltas BM; Sboner A; Mosquera JM; Elemento O; Nanus DM; Tagawa ST; Ballman KV; Beltran H
    Eur J Cancer; 2019 Nov; 121():7-18. PubMed ID: 31525487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
    Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
    Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mixed primary prostatic carcinoma with acinar, neuroendocrine and ductal components.
    Romero-Rojas AE; Diaz-Perez JA; Reddy A
    Arch Ital Urol Androl; 2014 Jun; 86(2):150-1. PubMed ID: 25017603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive serial molecular profiling of an "N of 1" exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment.
    Kadakia KC; Tomlins SA; Sanghvi SK; Cani AK; Omata K; Hovelson DH; Liu CJ; Cooney KA
    J Hematol Oncol; 2015 Oct; 8():109. PubMed ID: 26444865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Japanese patient with ductal carcinoma of the prostate carrying an adenomatosis polyposis coli gene mutation: a case report.
    Umeda K; Kosaka T; Nakamura K; Takeda T; Mikami S; Nishihara H; Oya M
    Diagn Pathol; 2020 Aug; 15(1):102. PubMed ID: 32758244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.
    Lotan TL; Toubaji A; Albadine R; Latour M; Herawi M; Meeker AK; DeMarzo AM; Platz EA; Epstein JI; Netto GJ
    Mod Pathol; 2009 Mar; 22(3):359-65. PubMed ID: 19151660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.